Literature DB >> 15684649

Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration.

Corinna Van Den Heuvel1, James J Donkin, John W Finnie, Peter C Blumbergs, Tim Kuchel, Barbara Koszyca, Jim Manavis, Nigel R Jones, Peter L Reilly, Robert Vink.   

Abstract

The aim of these studies was to assess and quantitate the effects of cyclosporin-A (CyA) on brain APP messenger RNA and neuronal perikaryal APP antigen expression following controlled focal head impact in sheep. Impact results in a significant increase in both APP mRNA and neuronal perikaryal APP antigen expression. Post-traumatic administration of CyA (intrathecal 10 mg/kg) resulted in a reduction in APP mRNA and neuronal perikaryal antigen expression. At 2 h postinjury, CyA treatment caused a statistically significant (p < 0.05) 1.3 +/- 0.1-fold decrease in APP mRNA in the central gray matter of impacted sheep compared to untreated impacted sheep. A more profound reduction in APP mRNA synthesis (1.6 +/- 0.2 fold) was evident at 6 h (p < 0.05). The mean percentage brain area with APP immunoreactive neuronal perikarya at 6 h post-injury was 94.5% in untreated impacted animals, 10.0% in CyA-treated impacted animals, 5.5% in untreated nonimpacted animals, and 6% in CyA-treated non-impacted controls. These results demonstrate that CyA has a downregulatory effect on increased APP expression caused by TBI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15684649     DOI: 10.1089/neu.2004.21.1562

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  8 in total

1.  Improvement of cerebral function by anti-amyloid precursor protein antibody infusion after traumatic brain injury in rats.

Authors:  Tatsuki Itoh; Takao Satou; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Hiroyuki Ito
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

Review 2.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 3.  Inflammation in acute CNS injury: a focus on the role of substance P.

Authors:  F Corrigan; R Vink; R J Turner
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

4.  Dosing and safety of cyclosporine in patients with severe brain injury.

Authors:  Jimmi Hatton; Bonnie Rosbolt; Philip Empey; Richard Kryscio; Byron Young
Journal:  J Neurosurg       Date:  2008-10       Impact factor: 5.115

Review 5.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

Review 6.  Unlocking the Door to Neuronal Woes in Alzheimer's Disease: Aβ and Mitochondrial Permeability Transition Pore.

Authors:  Heng Du; Shirley ShiDu Yan
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-14

7.  Reproducibility and Characterization of Head Kinematics During a Large Animal Acceleration Model of Traumatic Brain Injury.

Authors:  Andrew R Mayer; Josef M Ling; Andrew B Dodd; Julie G Rannou-Latella; David D Stephenson; Rebecca J Dodd; Carissa J Mehos; Declan A Patton; D Kacy Cullen; Victoria E Johnson; Sharvani Pabbathi Reddy; Cidney R Robertson-Benta; Andrew P Gigliotti; Timothy B Meier; Meghan S Vermillion; Douglas H Smith; Rachel Kinsler
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

8.  Molecular Dissection of Cyclosporin A's Neuroprotective Effect Reveals Potential Therapeutics for Ischemic Brain Injury.

Authors:  Minoru Kawakami
Journal:  Brain Sci       Date:  2013-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.